Peanut allergy affects roughly 2% of children in Western countries and has historically been managed through strict avoidance — a strategy that does little to reduce underlying immune sensitization and carries significant quality-of-life costs. Emerging clinical evidence is now challenging that paradigm, offering both preventive and active therapeutic pathways that could fundamentally change how allergists counsel families.
The NEJM review synthesizes current evidence on early-life peanut introduction as a preventive strategy, building on landmark data showing that introducing allergenic foods before 12 months of age can reduce sensitization risk by over 80% in high-risk infants. On the treatment side, the review covers oral immunotherapy (OIT) protocols — including the FDA-approved Palforzia formulation — which expose patients to incrementally increasing doses of peanut protein to achieve desensitization. The review also addresses subcutaneous and epicutaneous immunotherapy options, patient selection criteria, and dosing thresholds required to achieve meaningful protection versus full sustained unresponsiveness.
What makes this clinical picture particularly important is the distinction between desensitization and tolerance. Most OIT protocols reliably raise the threshold at which a patient reacts — a meaningful safety buffer for accidental exposures — but do not reliably produce permanent immunological tolerance once treatment stops. This gap remains the central challenge in the field. Additionally, OIT carries a non-trivial risk of adverse reactions, including anaphylaxis during build-up phases, which demands careful patient selection and supervised dosing escalations. For health-conscious adults managing children with food allergies, the practical takeaway is that both timing of introduction and the availability of structured immunotherapy programs now offer options that pure avoidance never could. This review represents a consolidation of confirmatory evidence rather than a paradigm shift, but its clinical utility for practitioners making daily management decisions is high.